3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
about
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.Breast cancer treatment-induced cardiotoxicity.Breast cancer in Angola, molecular subtypes: a first glanceUnusual case of splenic sarcoidosis without morphological lesions detected by PET-CT in a patient with breast cancer: functional imaging between pitfalls and therapeutic guide.Metastasis to the pancreas and stomach from a breast cancer primary: a case report.PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.Correlation of Trastuzumab-based Treatment with Clinical Characteristics and Prognosis in HER2-Positive Gastric and gastroesophageal Junction Cancer: A retrospective single center analysis.Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.Hybrid 18F-FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy.Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.Reply to Katsu and Baker: Using zebrafish PDX to screen drug sensitivity of endocrine-dependent cancers.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients."Lazarus Response" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion.Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phaMale breast cancer: finding the way in this uncommon path.Practical consensus recommendations regarding the use of hormonal therapy in metastatic breast cancer.Prediction of Chemoresistance in Women Undergoing Neo-Adjuvant Chemotherapy for Locally Advanced Breast Cancer: Volumetric Analysis of First-Order Textural Features Extracted from Multiparametric MRI.Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial).Advances in the systemic treatment of triple-negative breast cancer.Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review.Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer.Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis.Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines.Should age impact breast cancer management in young women? Fine tuning of treatment guidelines.Pituitary, Gonadal, Thyroid Hormones and Endocrine Disruptors in Pre and Postmenopausal Nigerian Women with ER-, PR- and HER-2-Positive and Negative Breast Cancers.The Development of Quality of Life Questionnaire for Indonesian Breast Cancer Patients: INA-BCHRQoLLong-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" studyClinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidenceEndocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and LiteratureCure in metastatic breast cancerLate Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast CancerEpigenetic profiling for the molecular classification of metastatic brain tumors
P2860
Q31157714-6DB22485-4848-42C8-9E88-5CFA668EF8F3Q38661390-8020424D-67DC-4285-AE08-D4EA225AD006Q39428826-43EA2DEE-8757-4BD8-8D55-27C493870593Q41545885-906979B1-402F-421F-922E-21E29094C114Q41683793-E81B3D18-550D-4E37-8D1E-3B15B179BB9CQ42375452-7FB4EC53-6CE5-45A6-A6D0-AA85292A5DD3Q45069110-77B7A8B2-2DFD-4F22-B5FA-9646678472D3Q45070735-82205D10-A820-4011-859D-D2F2DD5B05F1Q47190729-D261AAB8-6963-4DCC-AC29-3A73D0A9B492Q47321026-AFB241F6-C800-4A0C-8E46-908D6BCDD082Q47370686-6AFADBAE-7C32-44F1-84FB-AF7A6C90842DQ47578323-97F967EA-F8AB-4695-91D8-AD916E2FBCD5Q47593035-9BB191CB-B5D1-4E13-8532-6417875EEA01Q47894494-58E31675-2211-4403-9115-6D1BD373515FQ48243603-1DB2BC35-B2E7-4434-9A57-38C7C75C63E1Q48257534-264ADBA7-1C38-409A-997D-A2B8A747FE9EQ48297177-16F87B5D-44EA-482D-8886-C371DA8C5E01Q48327802-0F31A9B1-2661-47A2-9097-65EF6639DAD1Q51763818-0CDA66F2-9DB0-4023-8E0D-01F8D4705760Q52578959-F2AAB32B-10C7-4AC6-9B52-50758DC13609Q52590701-8D03A20F-64CD-418B-8353-C710BA9CB4B2Q52888317-ABDF674F-56C1-497E-9457-01A20543F548Q54775458-B6AF3447-340A-4317-936D-907659AD4E59Q54940165-DB2BD151-F21B-49A9-912E-016F2C351E36Q54945957-0D72F70F-7F6C-47CD-972A-A49E23437ABDQ54963093-3C1B2EEA-AF7A-42CE-B39F-0C28E32C9C40Q55105639-AB0C247A-2746-44B6-AC3C-63686C08DB00Q55206362-3470CBB4-66A8-41B1-A1BC-DA630B05CDB4Q55310990-6D1D89BB-079D-4F7C-9023-3733F0223D4DQ55361350-B9827A56-0398-4DEF-BE11-0B1421B24B4CQ55423791-3656ABC8-582F-4A25-B243-9353912D0799Q55431604-F0AA05BE-8B5D-4AFB-B96D-8024C67D0C27Q55439552-264ED469-430C-44EE-8F50-5A24FE07EE2EQ55709549-84B365DC-590B-43D0-9E12-A6A8CCB097DCQ57074570-BFF4B389-0C79-459C-A0BD-5DD730935131Q57107345-337CEBBF-4419-4863-BBDC-CC063A3B8B1CQ57108908-2391F8DB-9F68-468C-BE70-11C72360200EQ57115279-54F3781B-B718-4DA7-BFAE-FC69AAF108B1Q57495756-98CAF5C9-3934-45F1-979D-ED600E6ED236Q58608173-E2E0CA8C-B83D-45CA-8B0E-6B318534CB16
P2860
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
@en
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer
@nl
type
label
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
@en
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer
@nl
prefLabel
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
@en
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer
@nl
P2093
P2860
P50
P356
P1433
P1476
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
@en
P2093
C H Barrios
C Thomssen
D Corneliussen-James
P2860
P356
10.1093/ANNONC/MDW544
P50
P577
2017-01-01T00:00:00Z